X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20637) 20637
Magazine Article (150) 150
Newsletter (133) 133
Book Chapter (52) 52
Newspaper Article (25) 25
Publication (16) 16
Reference (9) 9
Book Review (7) 7
Book / eBook (4) 4
Transcript (4) 4
Conference Proceeding (2) 2
Dissertation (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18699) 18699
antihypertensive agents - therapeutic use (11936) 11936
hypertension - drug therapy (10373) 10373
male (10211) 10211
female (9955) 9955
antihypertensive agents - adverse effects (8624) 8624
middle aged (8045) 8045
hypertension (7743) 7743
aged (6970) 6970
adult (5381) 5381
blood pressure - drug effects (4860) 4860
antihypertensive agents - administration & dosage (4042) 4042
treatment outcome (3847) 3847
hypertension - physiopathology (3425) 3425
blood pressure (3378) 3378
risk factors (3378) 3378
pharmacology & pharmacy (2958) 2958
peripheral vascular disease (2668) 2668
drug therapy, combination (2617) 2617
blood-pressure (2376) 2376
hypertension - complications (2318) 2318
antihypertensive agents - pharmacology (2173) 2173
drug therapy (2123) 2123
antihypertensive drugs (2122) 2122
medicine, general & internal (2022) 2022
aged, 80 and over (1975) 1975
double-blind method (1830) 1830
cardiac & cardiovascular systems (1820) 1820
animals (1784) 1784
medicine & public health (1609) 1609
mortality (1602) 1602
time factors (1570) 1570
angiotensin-converting enzyme inhibitors - therapeutic use (1531) 1531
prospective studies (1514) 1514
care and treatment (1427) 1427
risk (1340) 1340
research (1308) 1308
therapy (1301) 1301
hypertension - diagnosis (1251) 1251
internal medicine (1248) 1248
management (1162) 1162
calcium channel blockers - therapeutic use (1158) 1158
diuretics (1130) 1130
dose-response relationship, drug (1094) 1094
health aspects (1090) 1090
ophthalmology (1081) 1081
adolescent (1068) 1068
clinical trials as topic (1057) 1057
hypertension - epidemiology (1054) 1054
follow-up studies (1051) 1051
prevalence (1028) 1028
analysis (1023) 1023
prevention (1021) 1021
retrospective studies (1014) 1014
randomized controlled trials as topic (1013) 1013
double-blind (988) 988
diabetes (976) 976
adrenergic beta-antagonists - therapeutic use (960) 960
angiotensin-converting enzyme inhibitors - adverse effects (949) 949
antihypertensives (934) 934
drug combinations (914) 914
antihypertensive agents (895) 895
dosage and administration (889) 889
diuretics - therapeutic use (882) 882
cardiovascular disease (866) 866
intraocular pressure - drug effects (862) 862
hypertension - etiology (841) 841
disease (834) 834
tetrazoles - therapeutic use (826) 826
drugs (817) 817
cardiology (816) 816
abridged index medicus (814) 814
efficacy (808) 808
angiotensin (804) 804
heart rate - drug effects (802) 802
blood pressure - physiology (786) 786
hypertension, pulmonary - drug therapy (784) 784
calcium channel blockers - adverse effects (783) 783
glaucoma (775) 775
clinical trials (758) 758
pregnancy (745) 745
risk assessment (745) 745
stroke (744) 744
rats (727) 727
trial (724) 724
drug interactions (723) 723
cardiovascular diseases - prevention & control (719) 719
amlodipine (699) 699
urology & nephrology (697) 697
age factors (695) 695
antihypertensive agents - pharmacokinetics (692) 692
cardiovascular diseases (689) 689
tetrazoles - adverse effects (681) 681
safety (674) 674
young adult (671) 671
angiotensin ii type 1 receptor blockers - therapeutic use (658) 658
patient compliance (654) 654
patients (653) 653
hydrochlorothiazide (636) 636
hypertension - therapy (633) 633
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19132) 19132
German (712) 712
French (387) 387
Japanese (231) 231
Spanish (200) 200
Russian (193) 193
Italian (95) 95
Portuguese (60) 60
Swedish (52) 52
Norwegian (48) 48
Chinese (46) 46
Danish (43) 43
Polish (42) 42
Dutch (39) 39
Czech (34) 34
Hungarian (30) 30
Romanian (21) 21
Finnish (16) 16
Bulgarian (11) 11
Hebrew (11) 11
Croatian (8) 8
Serbian (5) 5
Slovak (5) 5
Turkish (5) 5
Ukrainian (5) 5
Lithuanian (2) 2
Greek (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Archives of Dermatological Research, ISSN 0340-3696, 1/2009, Volume 301, Issue 1, pp. 99 - 105
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation... 
Drug-induced lupus erythematosus | Antinuclear antibodies (ANA) | Medicine & Public Health | Dermatology | Anti-TNFα-induced lupus | Anti-histone antibodies | Subacute cutaneous drug-induced lupus (SCLE) | Drug reactions | RHEUMATOID-ARTHRITIS | AUTOANTIBODIES | ANTINUCLEAR | NECROSIS-FACTOR-ALPHA | INDUCTION | DERMATOLOGY | Anti-TNF alpha-induced lupus | THERAPY | INFLIXIMAB | ASSOCIATION | EPIDEMIOLOGY | PSORIASIS | Antifungal Agents - adverse effects | Antitubercular Agents - adverse effects | Naphthalenes - adverse effects | Antibodies - metabolism | Calcium Channel Blockers - adverse effects | Serositis | Exanthema | Humans | Isoniazid - adverse effects | Interferons - adverse effects | Antihypertensive Agents - administration & dosage | Sodium Chloride Symporter Inhibitors - adverse effects | Arthritis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Lupus Erythematosus, Systemic - immunology | Sodium Chloride Symporter Inhibitors - administration & dosage | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Lupus Erythematosus, Cutaneous - chemically induced | Procainamide - administration & dosage | Lupus Erythematosus, Cutaneous - immunology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Procainamide - adverse effects | Antihypertensive Agents - adverse effects | Hydralazine - adverse effects | Isoniazid - administration & dosage | Lupus Erythematosus, Systemic - diagnosis | Interferons - administration & dosage | Hydralazine - administration & dosage | Animals | Anti-Arrhythmia Agents - adverse effects | Naphthalenes - administration & dosage | Calcium Channel Blockers - administration & dosage | Antitubercular Agents - administration & dosage | Lupus Erythematosus, Systemic - chemically induced | Antifungal Agents - administration & dosage | Lupus Erythematosus, Cutaneous - diagnosis | Lupus | Antigen-antibody reactions | Enzymes | Antigens | Biological products | Antibodies | Viral antibodies | Enzyme inhibitors | Systemic lupus erythematosus | Fluocinolone acetonide | Calcium channel blockers | Diuretics | Kidney diseases | Hydralazine | Index Medicus
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 3, p. CD009868
...‐fatal ASCVD events, and adverse events. We also sought to determine the effect of fixed... 
Blood Pressure | Drugs | A.1 Drugs | Anticholesteremic Agents | Aspirin | Cardiovascular Diseases | Heart disease prevention | Costs | A.1.3 Other | Placebo Effect | A. Cardiovascular Disease: Primary Prevention | Insurance medicine | Cause of Death | Cholesterol | Randomized Controlled Trials as Topic | Prevention | Platelet Aggregation Inhibitors | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Drug Combinations | POLYPILL-BASED STRATEGY | Humans | Antihypertensive Agents [administration & dosage] | Anticholesteremic Agents [administration & dosage] | Cardiovascular Diseases [mortality; prevention & control] | RANDOMIZED CONTROLLED-TRIAL | PROACTIVE MULTIFACTORIAL INTERVENTION | Aspirin [administration & dosage] | USUAL CARE | MEDICINE, GENERAL & INTERNAL | Platelet Aggregation Inhibitors [administration & dosage] | HIGH-RISK | DOUBLE-BLIND | SINGLE-PILL COMBINATION | BLOOD-PRESSURE CONTROL | PLACEBO-CONTROLLED TRIAL | CORONARY-HEART-DISEASE | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Anticholesteremic Agents - adverse effects | Antihypertensive Agents - adverse effects | Aspirin - administration & dosage | Aspirin - adverse effects | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Platelet Aggregation Inhibitors - adverse effects
Journal Article
Cochrane library, ISSN 1465-1858, 2014, Volume 2014, Issue 8, p. CD009096
.... Objectives To compare the effects of ACE inhibitors and ARBs on total mortality and cardiovascular events, and their rates of withdrawals due to adverse effects (WDAEs... 
Hypertension | Kidney disease | Treatment: pharmacological | Stroke | Angiotensin Receptor Antagonists | Angiostensin‐converting enzyme (ACE) inhibitors | Pharmacological Therapies | Hypotension | Angiotensin‐Converting Enzyme Inhibitors | Randomized Controlled Trials as Topic | Heart Diseases | Antihypertensive Agents | Heart & circulation | Essential Hypertension | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | LONG-TERM | Antihypertensive Agents [adverse effects; therapeutic use] | LOSARTAN | Randomized Controlled Trials as Topic Stroke [mortality] | MYOCARDIAL-INFARCTION | Angiotensin-Converting Enzyme Inhibitors [adverse effects; therapeutic use] | HEART-FAILURE | RANDOMIZED CONTROLLED-TRIAL | COMBINATION | Heart Diseases [mortality] | MEDICINE, GENERAL & INTERNAL | HIGH-RISK PATIENTS | Hypertension [complications; drug therapy; mortality] | RAMIPRIL | P-WAVE DISPERSION | LEFT-VENTRICULAR MASS | Angiotensin Receptor Antagonists [adverse effects; therapeutic use] | Humans | Hypertension - drug therapy | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Heart Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Hypertension - complications | Hypertension - mortality | Stroke - mortality | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects
Journal Article
Diabetes care, ISSN 1935-5548, 2015, Volume 38, Issue 3, pp. 420 - 428
Journal Article
Cochrane library, ISSN 1465-1858, 2015, Volume 2015, Issue 5, p. CD003825
...) evidence has not been conducted. Objectives To determine the dose‐related decrease in systolic or diastolic blood pressure, or both, as well as adverse events leading to participant withdrawal and adverse biochemical effects... 
Blood Pressure | Hypertension | Kidney disease | Pyridines | Treatment: pharmacological | Sodium Potassium Chloride Symporter Inhibitors | Indans | Pharmacological Therapies | Furosemide | Randomized Controlled Trials as Topic | Dose‐Response Relationship, Drug | Sulfonamides | Thiazoles | Diuretics | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | CONTROLLED-TRIAL | PLACEBO | SLOW-RELEASE FRUSEMIDE | Hypertension [drug therapy] | Humans | HEART-FAILURE | FUROSEMIDE THERAPY | SYSTEMIC HYPERTENSION | Dose-Response Relationship, Drug | MEDICINE, GENERAL & INTERNAL | Blood Pressure [drug effects] | DOUBLE-BLIND | Sodium Potassium Chloride Symporter Inhibitors [administration & dosage; adverse effects] | MODERATE HYPERTENSION | FIXED-DOSE COMBINATION | SYSTOLIC DYSFUNCTION | Antihypertensive Agents [administration & dosage; adverse effects] | Indans - adverse effects | Furosemide - administration & dosage | Pyridines - administration & dosage | Sodium Potassium Chloride Symporter Inhibitors - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Thiazoles - administration & dosage | Thiazoles - adverse effects | Antihypertensive Agents - adverse effects | Pyridines - adverse effects | Furosemide - adverse effects | Sulfonamides - adverse effects | Blood Pressure - drug effects | Indans - administration & dosage | Sodium Potassium Chloride Symporter Inhibitors - administration & dosage | Sulfonamides - administration & dosage
Journal Article
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 02/2007, Volume 49, Issue 2, pp. 276 - 284
Thiazide diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers all cause reactive rises in plasma renin activity. We... 
Hypertension | Aliskiren | Renin inhibitor | Renin-angiotensin-aldosterone system | Combination therapy | Plasma renin activity | Ambulatory blood pressure measurement | SYSTEM | plasma renin activity | DESIGN | ANTAGONIST | MYOCARDIAL-INFARCTION | aliskiren | TISSUE | ambulatory blood pressure measurement | SOCIETY | renin-angiotensin-aldosterone system | RISK-FACTOR | combination therapy | PERIPHERAL VASCULAR DISEASE | renin inhibitor | ESSENTIAL-HYPERTENSION | ALDOSTERONE | hypertension | Angiotensin II Type 1 Receptor Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Amides | Hypertension - drug therapy | Male | Sodium Chloride Symporter Inhibitors - adverse effects | Sodium Chloride Symporter Inhibitors - therapeutic use | Biphenyl Compounds - therapeutic use | Hypertension - blood | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Drug Therapy, Combination | Hypertension - diagnosis | Ramipril - adverse effects | Hydrochlorothiazide - adverse effects | Fumarates - therapeutic use | Fumarates - adverse effects | Antihypertensive Agents - therapeutic use | Renin - blood | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Fumarates - blood | Renin - antagonists & inhibitors | Tetrazoles - therapeutic use | Aged | Patient Compliance | Tetrazoles - adverse effects | Blood Pressure Monitoring, Ambulatory | Hydrochlorothiazide - therapeutic use
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 375, Issue 9721, pp. 1173 - 1181
.... We assessed the effects of these drug combinations on progression of chronic kidney disease... 
Internal Medicine | AMLODIPINE | MORTALITY | BENAZEPRIL | MEDICINE, GENERAL & INTERNAL | CONVERTING-ENZYME-INHIBITOR | ALBUMINURIA | DISEASE | NITRIC-OXIDE | DIABETIC-NEPHROPATHY | PROGRESSION | Blood Pressure | Calcium Channel Blockers - adverse effects | Benzazepines - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Kidney Failure, Chronic - urine | Male | Albuminuria | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Amlodipine - administration & dosage | Hydrochlorothiazide - adverse effects | Kidney Failure, Chronic - physiopathology | Diuretics - administration & dosage | Glomerular Filtration Rate | Double-Blind Method | Risk Factors | Amlodipine - adverse effects | Hydrochlorothiazide - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Disease Progression | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Calcium Channel Blockers - administration & dosage | Kidney Failure, Chronic - complications | Creatinine - blood | Hypertension - complications | Aged | Benzazepines - administration & dosage | Diuretics - adverse effects | Drug Combinations | Hypertension | Chronic kidney failure | Patient outcomes | Development and progression | Drug therapy, Combination | Drug therapy | Methods | Risk factors | Studies | Heart failure | Blister packs | Mortality | Kidney diseases | Diabetes | Drugs | blood pressure | Side effects | Filtration | secondary analysis | Dialysis | clinical trials | hypertension | Kidney
Journal Article
Hypertension (Dallas, Tex. 1979), ISSN 1524-4563, 2007, Volume 49, Issue 4, pp. 839 - 845
Journal Article